<?xml version="1.0" encoding="UTF-8"?>
<p id="p0205">Palivizumab is a monoclonal antibody against RSV F glycoprotein, which may be administered prophylactically to reduce the risk of severe bronchiolitis and hospitalization in specially vulnerable children, i.e. preterm infants and children with chronic lung or heart diseases (
 <xref rid="bb0040" ref-type="bibr">Jartti et al., 2019</xref>). The antivirals cidofovir and ribavirin have been used against RSV especially in immunocompromised patients, but little to no beneficial and many adverse effects have been observed. Consequently, their widespread use is not recommended (
 <xref rid="bb0045" ref-type="bibr">Khanal et al., 2018</xref>).
</p>
